💸 The Tape

While everyone watches Washington, the most consequential consolidation story in cannabis is unfolding in Florida 

Florida remains the crown jewel of American medical cannabis: 938,435 qualified patients with active ID cards, 771 dispensing locations, and — per the state's July 24 weekly report — 411.9 million milligrams of THC dispensed in a single week, alongside more than 146,000 ounces of smokable flower. Annualize that volume and you're looking at the largest medical cannabis market in the country, operating under a vertically integrated, limited-license structure that rewards scale like nowhere else.

The Top Five: Who Runs Florida

The OMMU's weekly dispensation report is the industry's most transparent scoreboard, and the July 17–23 numbers tell a clear story.

Trulieve remains in a league of its own: 170 dispensing locations moved 106.2 million mg of THC and 49,493 ounces of smokable flower in one week — more than a quarter of the entire state's volume, and more than the next two competitors combined. Roughly 625,000 mg per store per week, at a footprint more than double anyone else's. This is what a decade of first-mover discipline looks like.

MÜV (Verano) holds the clear second position: 86 locations, 48.9 million mg, and 16,678 smokable ounces. Curaleaf sits just behind at 75 locations and 47.2 million mg — and notably posts the highest per-store productivity among the majors at roughly 629,000 mg per location. Ayr Cannabis Dispensary — now operating under creditor-owned Arboretum — runs 65 stores doing 37.7 million mg. And Surterra Wellness (Parallel) rounds out the top five by footprint at 44 locations, though its 14.5 million mg shows a productivity gap that smaller rivals are exploiting.

One honorable mention demands attention: GTI Florida generates 18.9 million mg from just 22 stores — approximately 860,000 mg per location, the highest productivity in the state. Sunburn (750,000 mg/store) and Jungle Boys show the same pattern: newer, brand-led operators winning on velocity rather than footprint.

The Vireo Assembly: A Top-Four Operator Built From Three Logos

Now overlay Vireo Growth's acquisition spree onto this scoreboard, because something remarkable emerges from the OMMU table when you combine three separate line items: FLUENT, Green Dragon, and Planet 13.

The pieces arrived through three distinct transactions. First came FLUENT, acquired via a $30 million debt equitization announced in Vireo's January deal wave — bringing 33 Florida dispensing locations currently moving 13.5 million mg weekly. Then the Eaze acquisition delivered more than California delivery: Eaze owned the Green Dragon retail platform, whose Florida operation spans 41 locations dispensing 15.9 million mg — quietly the sixth-largest footprint in the state. And this week, Vireo announced its all-stock merger with Planet 13 at a 16.6% premium to 20-day VWAP as of July 24, and a 24% premium to the July 24 closing price — adding 34 Florida locations, 8.7 million mg in weekly volume.

Combine the three OMMU line items and the pro forma entity is striking: 108 dispensing locations moving 38.1 million mg of THC and roughly 13,900 smokable ounces per week. On store count, that's the second-largest retail footprint in Florida — vaulting past MÜV's 86 and trailing only Trulieve's 170. On volume, the combined platform lands at number four — 38.1 million mg edging past Ayr's 37.7 million, behind Curaleaf and MÜV.

The gap between those two rankings is the entire investment thesis. Vireo's combined Florida per-store productivity sits around 353,000 mg per week — roughly half of what Trulieve, Curaleaf, and MÜV extract per location, and barely 40% of GTI's benchmark. Three brands, three loyalty programs, three supply chains, and three cultivation platforms serving 108 stores at sub-scale velocity. That's either a permanent drag — or the largest same-store-sales opportunity in Florida. If integration lifts the combined platform merely to MÜV-level productivity, the same 108 doors would generate over 61 million mg weekly — a top-two volume position without opening a single new store.

Setting the Tone: What Florida Looks Like From Here

The next chapter of Florida cannabis will be defined by three forces, and this consolidation sits at the center of all of them.

First, the market is bifurcating. The OMMU data shows a widening split between high-velocity operators (Trulieve, GTI, Sunburn, Jungle Boys) and footprint-heavy laggards (Surterra, the long tail of sub-20-store MMTCs). Vireo's bet is that scale plus operational discipline can convert laggard assets into velocity assets. The weekly OMMU reports will grade that homework in public, every Friday.

Second, the catalysts are real — but the biggest one may be further away than the headlines suggest. Federal 280E relief is already flowing to Florida's medical operators, DEA registrations are converting the state's dispensaries into federally recognized facilities, and the November hemp ban is poised to push consumers back toward licensed channels. But the adult-use timeline deserves sober handicapping. The next realistic window is 2028 or beyond, meaning operators must underwrite Florida as a medical-only market for years, not months. That reframes everything: the 938,000-patient registry, growing steadily on the back of expanded conditions and the Supreme Court's gun-rights ruling, isn't a placeholder awaiting conversion. It is the market — and winning it on medical economics is the only strategy that doesn't require a ballot miracle.

Third, the consolidation window stays open longer — and that cuts both ways. FLUENT came through distressed debt. Planet 13 came at a modest premium after years of Florida struggles. In a medical-only Florida stretching to 2028 and beyond, distressed assets keep surfacing: sub-scale MMTCs burning cash at 350,000 mg per store per week can't wait indefinitely for an adult-use bailout, and each year without conversion shakes more of them loose at bottom-cycle prices. That's the patient consolidator's advantage — Vireo and any followers get more time to buy cheap, but they also inherit the burden of making medical-market math work now, without adult-use multiples riding to the rescue. Watch the remaining independents on the OMMU table: Sunburn, Jungle Boys, The Flowery, Goldflower. The high-velocity names can thrive on medical economics indefinitely; the laggards face a harder question every Friday the report drops. Every one of them is either a future consolidator, a future target — or, in a prolonged medical-only market, a future casualty.

The scoreboard updates every Friday. In Florida, nobody gets to hide — and now, nobody gets to wait for November to save them either.

📈 Dog Walkers

$LEEEF ( ▼ 4.64% ) Taps The Capital Markets

LEEF Brands just closed the capital that completes its supply chain — and the oversubscription tells you investors see what's being built.

The California extraction leader announced the final closing of its oversubscribed financing, bringing total gross proceeds across all tranches to approximately US$14.5 million. The final closing added $5.2 million in fresh capital through the issuance of 20.8 million Series A-2 preferred shares at US$0.25 per share, alongside an exchange converting existing Series A-1 holders into the new series. Insider Jamie Mendola participated in the exchange — continued skin in the game from the board level.

The use of proceeds is precise: purchasing a cannabis processing and storage facility that will dry, cure, freeze, and store biomass harvested at Salisbury Canyon Ranch before transport to LEEF Labs in Mendocino County for extraction. It's the missing link in a vertically integrated chain that now runs from one of California's largest cultivation sites through processing to the state's premier extraction platform.

The capacity math is forward-looking. The facility supports Salisbury Canyon Ranch's current output, accommodates the planned expansion to the ranch's fully permitted 180-acre footprint, and — critically — provides headroom for the two markets management keeps naming: interstate commerce and international export. The facility can also generate a third-party revenue stream by offering processing and storage services to other cultivators.

CEO Micah Anderson framed it as infrastructure for the long game: "We've built one of California's premier low-cost cultivation platforms at Salisbury Canyon Ranch. Owning our own processing and storage facility is the next step."

For a company that doubled gross margins to 49% last quarter while unit volumes grew 60%, the thesis is consistent: own the lowest-cost position in California's brutal market today, and be structurally ready the moment state lines — or national borders — open. The infrastructure keeps compounding.

📺 Trade To Black

Big Day For Cannabis Announcements, Bigger Questions Ahead | TTB Presented by Flowhub

• SNDL Goes South: SNDL completed its acquisition of Parallel's Florida, Texas, and Massachusetts assets — adding a 249-store retail network and positioning it as one of the first Nasdaq-listed companies with direct, consolidated exposure to U.S. medical cannabis operations.

• Glass House Preps for Export: The company retained former DEA compliance executive Matt Murphy to advise on interstate commerce and export opportunities, leveraging his experience building Colombia's first DEA-comparable compliance program at Khiron Life Sciences.

• Vireo's Crown: The Planet 13 acquisition pushes Vireo's Nevada and Florida footprint significantly higher — bringing its pro forma count to roughly 265 dispensaries across 15 states and positioning it as the largest U.S. cannabis operator by store count once pending deals close.

• Export Reality Check: Global cannabis consultant Deepak Anand separates fact from fiction on how U.S. cannabis exports will actually work — breaking down DEA applications, GMP compliance, and what operators genuinely need to understand before building business plans around international opportunities.